Movatterモバイル変換


[0]ホーム

URL:


AR130384A1 - COMPOSITIONS AND METHODS FOR TREATING LONG QT SYNDROME - Google Patents

COMPOSITIONS AND METHODS FOR TREATING LONG QT SYNDROME

Info

Publication number
AR130384A1
AR130384A1ARP230102339AARP230102339AAR130384A1AR 130384 A1AR130384 A1AR 130384A1AR P230102339 AARP230102339 AAR P230102339AAR P230102339 AARP230102339 AAR P230102339AAR 130384 A1AR130384 A1AR 130384A1
Authority
AR
Argentina
Prior art keywords
seq
set forth
amino acid
acid sequence
syndrome
Prior art date
Application number
ARP230102339A
Other languages
Spanish (es)
Inventor
Jin Li
Mustafa Kamani
Sylvia Fong
Bartlomiej Blus
Choong Sihn
- Nguyen Tu Ryoul
Original Assignee
Univ Of Bern
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Bern, Biomarin Pharm IncfiledCriticalUniv Of Bern
Publication of AR130384A1publicationCriticalpatent/AR130384A1/en

Links

Classifications

Landscapes

Abstract

Translated fromSpanish

En el presente documento se proporcionan anticuerpos humanizados anti-KCNQ1 y su uso en el tratamiento del síndrome de QT largo (LQTS). Reivindicación 1: Un anticuerpo aislado que se une específicamente a KCNQ1 que comprende una región variable de cadena pesada que comprende una secuencia de aminoácidos que es al menos 70% idéntica a una secuencia de aminoácidos establecida en la sec. con núm. de ident.: 4 o sec. con núm. de ident.: 7, y una región variable de cadena ligera que comprende una secuencia de aminoácidos que es al menos 70% idéntica a una secuencia de aminoácidos establecida en la sec. con núm. de ident.: 5, sec. con núm. de ident.: 8, sec. con núm. de ident.: 6 o sec. con núm. de ident.: 9. Reivindicación 3: El anticuerpo de la reivindicación 1 o la reivindicación 2, en donde el anticuerpo comprende HCDR1 establecido en la sec. con núm. de ident.: 10, HCDR2 establecido en la sec. con núm. de ident.: 11, HCDR3 establecido en la sec. con núm. de ident.: 12; LCDR1 establecido en la sec. con núm. de ident.: 13, LCDR2 que comprende la secuencia de aminoácidos “WAS” y LCDR3 establecido en la sec. con núm. de ident.: 14.Provided herein are humanized anti-KCNQ1 antibodies and their use in the treatment of long QT syndrome (LQTS). Claim 1: An isolated antibody that specifically binds to KCNQ1 comprising a heavy chain variable region comprising an amino acid sequence that is at least 70% identical to an amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 7, and a light chain variable region comprising an amino acid sequence that is at least 70% identical to an amino acid sequence set forth in SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 6 or SEQ ID NO: Claim 3: The antibody of claim 1 or claim 2, wherein the antibody comprises HCDR1 set forth in SEQ ID NO: 10, HCDR2 set forth in SEQ ID NO: 11, HCDR3 set forth in SEQ ID NO: 12; LCDR1 set forth in SEQ ID NO: 13, LCDR2 comprising the amino acid sequence “WAS” and LCDR3 set forth in SEQ ID NO: 14.

ARP230102339A2022-09-022023-09-01 COMPOSITIONS AND METHODS FOR TREATING LONG QT SYNDROMEAR130384A1 (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US202263374478P2022-09-022022-09-02

Publications (1)

Publication NumberPublication Date
AR130384A1true AR130384A1 (en)2024-12-04

Family

ID=88192357

Family Applications (1)

Application NumberTitlePriority DateFiling Date
ARP230102339AAR130384A1 (en)2022-09-022023-09-01 COMPOSITIONS AND METHODS FOR TREATING LONG QT SYNDROME

Country Status (3)

CountryLink
AR (1)AR130384A1 (en)
TW (1)TW202426484A (en)
WO (1)WO2024050526A1 (en)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3773919A (en)1969-10-231973-11-20Du PontPolylactide-drug mixtures
US4263428A (en)1978-03-241981-04-21The Regents Of The University Of CaliforniaBis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en)1980-02-251983-08-16The Trustees Of Columbia UniversityProcesses for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en)1981-02-161987-12-09Ici PlcContinuous release pharmaceutical compositions
EP0088046B1 (en)1982-02-171987-12-09Ciba-Geigy AgLipids in the aqueous phase
HUT35524A (en)1983-08-021985-07-29Hoechst AgProcess for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en)1983-11-011988-10-12TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATIONPharmaceutical composition containing urokinase
US4740461A (en)1983-12-271988-04-26Genetics Institute, Inc.Vectors and methods for transformation of eucaryotic cells
US5225539A (en)1986-03-271993-07-06Medical Research CouncilRecombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)1986-03-271986-04-30Winter G PRecombinant dna product
US4959455A (en)1986-07-141990-09-25Genetics Institute, Inc.Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en)1986-11-141990-03-27Genetics Institute, Inc.Eucaryotic expression system
US5223409A (en)1988-09-021993-06-29Protein Engineering Corp.Directed evolution of novel binding proteins
US5530101A (en)1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
GB9015198D0 (en)1990-07-101990-08-29Brien Caroline J OBinding substance
US5545806A (en)1990-08-291996-08-13Genpharm International, Inc.Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en)1990-08-292006-02-16Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
ES2113940T3 (en)1990-12-031998-05-16Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
US5780279A (en)1990-12-031998-07-14Genentech, Inc.Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
US5858657A (en)1992-05-151999-01-12Medical Research CouncilMethods for producing members of specific binding pairs
DE69230142T2 (en)1991-05-152000-03-09Cambridge Antibody Technology Ltd. METHOD FOR PRODUCING SPECIFIC BINDING PAIRS
US6225447B1 (en)1991-05-152001-05-01Cambridge Antibody Technology Ltd.Methods for producing members of specific binding pairs
US5639641A (en)1992-09-091997-06-17Immunogen Inc.Resurfacing of rodent antibodies
US5855885A (en)1993-01-221999-01-05Smith; RodgerIsolation and production of catalytic antibodies using phage technology
US5702892A (en)1995-05-091997-12-30The United States Of America As Represented By The Department Of Health And Human ServicesPhage-display of immunoglobulin heavy chain libraries
US6265150B1 (en)1995-06-072001-07-24Becton Dickinson & CompanyPhage antibodies
US5714352A (en)1996-03-201998-02-03Xenotech IncorporatedDirected switch-mediated DNA recombination
US6057098A (en)1997-04-042000-05-02Biosite Diagnostics, Inc.Polyvalent display libraries
JP2004511425A (en)2000-02-082004-04-15ザ ペン ステート リサーチ ファウンデーション Interleukin 13 receptor subunit alpha-2 used for immunotherapy
US7317091B2 (en)2002-03-012008-01-08Xencor, Inc.Optimized Fc variants
US9300829B2 (en)2014-04-042016-03-29Canon Kabushiki KaishaImage reading apparatus and correction method thereof
TW202323276A (en)*2021-09-032023-06-16瑞士伯恩大學Compositions and methods for treating long qt syndrome

Also Published As

Publication numberPublication date
TW202426484A (en)2024-07-01
WO2024050526A1 (en)2024-03-07

Similar Documents

PublicationPublication DateTitle
PE20210132A1 (en) ANTI-CD3 ANTIBODIES AND USES OF THEM
PE20200294A1 (en) ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE
PE20220218A1 (en) MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
PE20210045A1 (en) AGONIST ANTIBODIES AGAINST PD-1 AND USES OF THESE
PE20130226A1 (en) ANTIBODIES TOWARDS HUMAN GDF8
PE20212088A1 (en) ANTI-TAU ANTIBODIES AND THEIR USE
CO6230999A2 (en) ANTI-SCLEROSTINE ANTIBODY
IL277242B2 (en)Antibodies that bind cd39 and uses thereof
PE20181921A1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
AR110203A1 (en) ANTI-TIM-3 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES
PE20200011A1 (en) ANTI-PEPTIDE BETA AMYLOID N3pGlu ANTIBODIES AND THEIR USES
PE20130817A1 (en) PEPTIDE ANTIBODIES BETA AMYLOID ANTI-N3PGLU AND USES THEREOF
PE20181326A1 (en) ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND ITS USES
NZ610294A (en)Human antibodies to human tnf-like ligand 1a (tl1a)
NZ600768A (en)Human antibodies to human angiopoietin-like protein 4
PE20091351A1 (en) HUMANIZED ANTIBODIES SPECIFIC TO THE VON WILLEBRAND FACTOR
PE20141151A1 (en) CD27L ANTIGEN BINDING PROTEINS
ZA202211457B (en)Anti-cd73 antibody and use thereof
PE20090161A1 (en) MONOCLONAL ANTIBODIES ANTI CXCL13
PE20220708A1 (en) ANTI-CD73 ANTIBODIES
NZ592436A (en)Treatment with anti-alpha2 integrin antibodies
PE20230389A1 (en) PROTEINS THAT COMPRISE BINDING DOMAINS TO THE CD3 ANTIGEN AND USES OF THESE
AR110967A1 (en) MIMETIC ANTIBODIES FGF21 AND ITS USE
PE20240363A1 (en) ANTI-CCR8 ANTIBODIES AND USES THEREOF
PE20221337A1 (en) TREM2 ANTIBODIES AND THEIR USES

Legal Events

DateCodeTitleDescription
FBSuspension of granting procedure

[8]ページ先頭

©2009-2025 Movatter.jp